--- title: "New Weight Loss Drug Hailed as “Game Changer”" description: "According to a new study, the type 2 diabetes treatment drug called semaglutide could be an effective way to reduce weight in obese patients." date: "2021-02-12" modified: "2021-02-12" authors: - name: "Victor Tangermann" job_title: "Senior Editor" link: "https://futurism.com/authors/victor" url: "https://futurism.com/neoscope/weight-loss-drug-game-changer" categories: - "Health & Medicine" tags: - "obesity" - "Weight Loss" --- # New Weight Loss Drug Hailed as “Game Changer” ![According to a new study, the type 2 diabetes treatment drug called semaglutide could be an effective way to reduce weight in obese patients.]() *\Image: Futurism\* According to a promising new study, a diabetes treatment drug called semaglutide could be an effective way to reduce weight in obese patients, [*The New York Times* reports]() — but the findings come with numerous caveats. Researchers at Northwestern University in Chicago carried out an experiment involving almost 2,000 participants in 16 countries. Some participants injected themselves with semaglutide, while the rest received a placebo for 68 weeks, and both groups worked on nutrition and physical activity during the trial. The results, as detailed in [a paper]() published in the *New England Journal of Medicine* this week, were promising: participants who received the drug lost close to 15 percent of their body weight on average, and more than a third lost more than 20 percent. Participants in the placebo group, in contrast, lost only 2.4 percent of body weight on average. The drug also was able to reduce "cardiometabolic risk factors" and led to an increase in "participant-reported physical functioning," according to the paper. The drug, a synthetic hormone, works by tricking the brain into producing feelings of satiety. [Plenty]() of [medications]() and treatment plans, previously hailed as effective methods of losing weight, turned out to be far less effective than advertised, as the *Times* reports. But this time, the medical community seems genuinely excited. "This is the start of a new era of effective treatments for obesity," Robert Kushner, obesity researcher at Northwestern University and research lead, told the newspaper, describing the drug as a "game changer." The researchers are hoping the drug could be an effective alternative to invasive surgeries that very few people actually go through with. There are also a lot of things that could derail the drug's success. For one, Kushner is on the advisory board of Novo Nordisk, the pharmaceutical that produces semaglutide. The drug could also end up being prohibitively expensive, costing about $1,000 a month — and chances are that insurance companies won't cover that cost, according to the *Times*. Patients would also likely have to take the drug for a lifetime to keep their weight down. Big picture, any drug that promises to solve one of the stickiest medical issues facing Americans should be treated with a healthy dose of skepticism, particularly when those who call it a game changer advise the companies making the drug. And is it really fair to call it a "game changer?" [According to the CDC](), over 40 percent of Americans were obese in 2018, and that number is [only on the rise](). Prohibitively expensive drug treatments will arguably only play a small role in fighting obesity in the country, no matter how effective. ## Author I've been at Futurism since 2017, where my role has evolved to encompass design, writing, and increasingly editing. I've always been fascinated by space exploration and advanced transportation, which I've leaned into by interviewing luminaries in those fields while closely following the dimensions of policy and regulation that allow next-generation projects to succeed -- or, sometimes, to fail. I'm also keenly interested in the effects of generative AI on society, policies, and democratic institutions, as well as clean energy, physics and biology, and the vagaries of tech leadership. My work for Futurism has been cited by publications including Ars Technica, Gizmodo, PC Magazine, Jalopnik, Fox News, and the New York Post. I spent my childhood living in locations including Manila, the Philippines, and Geneva, Switzerland, attended McGill University, and now live in Toronto, Canada. Before Futurism I worked at AskMen and a small photography studio. In my free time, I'm an avid gardener, foodie, and craft beer lover, as well as a maker of artisanal hot pepper sauces. I have a magnificent dog named Freida. ### Author social links [Bluesky]()